Sources: 44NIH Clinical Center, 4ClinicalTrials, 6Cochrane Library, 65UMLS, 43NDF-RT, 13DrugBank, 26HMDB, 9DGIdb, 53PharmGKB, 30IUPHAR, 47Novoseek, 1BitterDBSee all MalaCards sources |
Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show top 50)
(show all 372)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Donepezil | approved | Phase 3, Phase 2 | 271 | 120014-06-4 | 3152 | ( inverted exclamation markA)-E 2020 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine 120014-06-4 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one AB1004836 AC-6969 AC1L1FAE AKOS000277311 Aricept Aricept ODT C24H29NO3 CHEBI:53289 CHEMBL502 CID3152 D07869 DB00843 Domepezil Donaz Donaz (TN) | Donepezil Donepezil (INN) Donepezil Hydrochloride Donepezil [INN:BAN] Donepezil hydrochloride Donepezilo Donepezilum Eranz I06-0343 KBio2_002144 KBio2_004712 KBio2_007280 KBioSS_002144 LS-81819 MolPort-000-881-588 MolPort-003-847-014 NCGC00167537-01 Oprea1_188452 Spectrum5_001662 Spectrum_001664 TL8000531 UNII-8SSC91326P |
| | 2 | | Lomustine | approved | Phase 3, Phase 1 | 76 | 13010-47-4 | 3950 | (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea (Cloro-2-etil)-1-cicloesil-3-nitrosourea (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian] 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas] 1-(2-Chloroethyl)-3-cyclohexylnitrosourea 13010-47-4 AC-10564 AC1L1H2T AI3-52779 BRN 2125058 Belustine Bristol Myers Squibb Brand of Lomustine Bristol-Myers Squibb Brand of Lomustine C9H16ClN3O2 CCNU CCNU [Chloroethyl nitrosoureas] CCRIS 860 CHEMBL514 CID3950 CINU Cecenu CeeNU CeeNU (TN) CeeNU, CCNU, Lomustine Ceenu Chloroethylcyclohexylnitrosourea Cyclohexyl chloroethyl nitrosourea D00363 D008130 DB01206 EINECS 235-859-2 FT-0083566 Gleostine | HMS2090A17 HSDB 6519 I06-0087 ICIG 1109 LS-728 Lomustina Lomustina [INN-Spanish] Lomustine Lomustine (USAN/INN) Lomustine [USAN:BAN:INN] Lomustine medac Brand Lomustinum Lomustinum [INN-Latin] MolPort-001-768-818 N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea NCGC00167466-01 NCI-C04740 NCI60_041743 NCIMech_000220 NPFAPI-06 NSC 79037 NSC-79037 NSC79037 OR5087 RB 1509 Rhone Poulenc Rorer Brand of Lomustine Rhone-Poulenc Rorer Brand of Lomustine S1840_Selleck SRI 2200 UNII-7BRF0Z81KG WLN: L6TJ AMVNNO&2G ZINC03831006 lomustine medac Brand of Lomustine | |
| | 3 | | Morphine | approved, investigational | Phase 3 | 855 | 57-27-2 | 5288826 | (-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (-)-Heroin hydrochloride (-)-Morphine (-)Morphine sulfate (5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol (5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol (5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol (7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL (7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol (−)-morphine 17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol 4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol 4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol 47106-99-0 57-27-2 6211-15-0 (sulfate (2:1) (salt) pentahydrate) 64-31-3 64-31-3 (sulfate (2:1) (salt) anhydrous) 7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol 8053-16-5 85201-37-2 Apokyn Astramorph PF Avinza BIDD:GT0147 C01516 CCRIS 5762 CHEBI:17303 CHEMBL70 CID5288826 Cube juice D-(-)-Morphine DB00295 DEA No. 9300 DepoDur Depodur Diacetylmorphine hydrochloride Diamorphine hydrochloride Dolcontin Dreamer Dulcontin Duramorph Duramorph PF Duromorph EINECS 200-320-2 Epimorph HSDB 2134 Hard stuff Heroin hydrochloride Heroine hydrochloride Hocus Infumorph | Kadian LS-91748 M-Eslon M.O.S MOI MORPHINE SULFATE MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE MS Contin MS/L MS/S MSIR Meconium MolPort-003-849-273 Morfina Morfina [Italian] Morphia Morphin Morphin [German] Morphina Morphina [Italian] Morphine Morphine Extra-Forte Morphine Forte Morphine H.P Morphine Sulfate Morphine [BAN] Morphinism Morphinum Morphitec Morphium Morpho Moscontin Ms Contin Ms Emma NSC11441 Nepenthe O,O'-Diacetylmorphine hydrochloride OMS Concentrate Oramorph SR Ospalivina RMS RMS Uniserts Rescudose Roxanol Roxanol 100 Roxanol UD SDZ 202-250 SDZ202-250 Statex Statex Drops Statex SR UNII-76I7G6D29C Unkie l-Morphine morphine nchembio.317-comp1 nchembio.64-comp1 |
| | 4 | | Methylphenidate | approved, investigational | Phase 3 | 364 | 113-45-1 | 4158 | .alpha.-Phenyl-2-piperidineacetic acid methyl ester 113-45-1 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester 2-Piperidineacetic acid, alpha-phenyl-, methyl ester 298-59-9 (hydrochloride) 4311/B Ciba AC1L1HJM C 4311 C07196 CHEBI:6887 CHEMBL796 CID4158 Calocain Centedein Centedrin Centedrine Centredin Concerta D-Methylphenidate HCl D04999 DB00422 DB06701 DEA No. 1724 Daytrana Daytrana (TN) EINECS 204-028-6 Focalin Focalin XR HSDB 3126 L001307 LS-565 METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R) MPH Meridil Metadate Metadate CD Metadate ER MethyPatch Methyl (2-phenyl-2-(2-piperidyl)acetate) Methyl alpha-phenyl-alpha-(2-piperidyl)acetate Methyl alpha-phenyl-alpha-2-piperidinylacetate Methyl phenidate Methyl phenidyl acetate | Methyl phenidylacetate Methylfenidan Methylin Methylin ER Methylofenidan Methylphen Methylphenidan Methylphenidate Methylphenidate (USAN/INN) Methylphenidate HCl Methylphenidate Hydrochloride Methylphenidate [INN:BAN] Methylphenidate hydrochloride Methylphenidatum Methylphenidatum [INN-Latin] Methylphenidylacetate hydrochloride Methypatch Metilfenidat hydrochloride Metilfenidato Metilfenidato [INN-Spanish] Metilfenidato [Italian] MolPort-001-779-620 NCI-C56280 PMS-Methylphenidate Phenidylate Plimasine Quillivant XR Riphenidate Ritalin Ritalin LA Ritalin SR Ritalin hydrochloride Ritalin-SR Ritaline Ritcher Works Ritcher works Tsentedrin UNII-207ZZ9QZ49 alpha-Phenyl-2-piperidineacetic acid methyl ester alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester d-methylphenidate HCl methyl 2-phenyl-2-piperidin-2-ylacetate methyl phenyl(piperidin-2-yl)acetate methylphenidate nchembio.2007.55-comp28 |
| | 5 | | Epoetin alfa | approved | Phase 3 | 626 | 113427-24-0 | | | Erythropoietin precursor Procrit | |
| | 6 | | Procarbazine | approved | Phase 3, Phase 2, Phase 1 | 68 | 671-16-9 | 4915 | 1-Methyl-2-(P-(isopropylcarbamoyl)benzyl)hydrazine 1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine 2-(P-Isopropylcarbamoylbenzyl)-1-methylhydrazine 2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine 366-70-1 (mono-hydrochloride) 4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide 4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide 671-16-9 AC-4547 AC1L1J8E Ambap671-16-9 BIDD:GT0183 BPBio1_001369 BRN 0958270 BSPBio_001244 Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI) C07402 C12H19N3O CAS-366-70-1 CB 400-497 CCRIS 2389 CHEMBL1321 CID4915 D08423 DB01168 EINECS 211-582-2 HMS2090J09 HSDB 3250 I01-8931 IBZ Ibenzmethyzin Ibenzmethyzine LS-7671 MBH MIH Matulane MolPort-005-940-370 N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide | N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine N-4-Isopropylcarbamoylbenzyl-n'-methylhydrazine N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide N-Isopropyl-P-(2-methylhydrazinomethyl)-benzamide N-Isopropyl-alpha-(2-methylhydrazino)-P-toluamide N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide NCGC00016438-01 NCGC00016438-02 NCI60_041703 NCIOpen2_004074 NSC-77213 Natulan Natulanar P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide PCX Prestwick0_001112 Prestwick1_001112 Prestwick2_001112 Prestwick3_001112 Procarbazin Procarbazin [German] Procarbazina Procarbazina [INN-Spanish] Procarbazine (INN) Procarbazine Monohydrochloride Procarbazine [INN:BAN] Procarbazine hydrochloride Procarbazinum Procarbazinum [INN-Latin] Ro 4-6467 Ro 4-6467/1 SPBio_003112 SRI-10847 UNII-35S93Y190K p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide procarbazine | |
| | 7 | | Vincristine | approved, investigational | Phase 3, Phase 1, Phase 2 | 863 | 2068-78-2, 57-22-7 | 5978 | 22-Oxovincaleukoblastin 22-Oxovincaleukoblastine 28379-27-3 57-22-7 AC1L1LJC C07204 C46H56N4O10 CCRIS 5763 CHEBI:28445 CID5978 D08679 DB00541 EINECS 200-318-1 HMS2090E19 HSDB 3199 Indole alkaloid LCR LS-228 Leurocristine Lilly 37231 (1:1 sulfate salt) Liposomal Vincristine Marqibo NCGC00163700-01 NCI-C04864 NCI60_026703 NSC-67574 Onco TCS | Oncovin Oncovin (1:1 sulfate salt) Oncovine Tecnocris Tecnocris (TN) UNII-5J49Q6B70F VCR VIN Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine Vincasar Vincasar (1:1 sulfate salt) Vincasar PFS Vincrex Vincrex (1:1 sulfate salt) Vincristin Vincristina Vincristina [DCIT] Vincristine (INN) Vincristine Sulfate Vincristine Sulfate PFS Vincristine [INN:BAN] Vincristinum Vincristinum [INN-Latin] Vincrstine Vincrystine Vinkristin Z-D-Val-Lys(Z)-OH vincristine | |
| | 8 | | Isotretinoin | approved | Phase 3, Phase 2, Phase 1 | 115 | 4759-48-2 | 5538, 5282379 | (13-cis)-Retinoate (13-cis)-Retinoic acid (13cis)-retinoic acid (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid (2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid (7E,9E,11E,13Z)-retinoic acid (7e,9e,11e,13Z)-Retinoic acid 13 Cis-Retinoic Acid 13 cis retinoic acid 13-RA 13-cis RA 13-cis retinoic acid 13-cis-Retinoate 13-cis-Retinoic acid 13-cis-Vitamin A acid 13-cis-Vitamin a acid 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid 4-09-00-02388 (Beilstein Handbook Reference) 4759-48-2 97950-17-9 AC-15388 AC1NQZZ4 Absorica Accutane Accutane (TN) Ambap302-79-4 Amnesteem BML2-E07 BPBio1_000080 BRD-K76723084-001-05-9 BRN 1885770 BSPBio_000072 BSPBio_001331 BSPBio_003345 CCRIS 4286 CHEBI:6067 CHEMBL547 CID5282379 CIP-Isotretinoin CPD000471891 Claravis Clarus D00348 D015474 EINECS 225-296-0 EU-0101081 Epuris HMS1361C13 HMS1568D14 HMS1791C13 HMS1921D08 HMS1989C13 HMS2092N07 HSDB 3929 IDI1_033801 Isotane Isotretinoin Isotretinoin (USP) | Isotretinoin Retinoic acid Isotretinoin Zinc Salt, 13 cis Isomer Isotretinoin Zinc Salt, 13-cis-Isomer Isotretinoin [USAN:BAN:INN] Isotretinoin [USAN:INN:BAN] Isotretinoina Isotretinoine Isotretinoine [INN-French] Isotretinoino Isotretinoino [INN-Spanish] Isotretinoinum Isotretinoinum [INN-Latin] Isotrex LMPR01090021 LS-143465 Lopac0_001081 MLS001074662 MolPort-003-666-394 Myorisan NCGC00094358-01 NCGC00094358-02 NCGC00094358-03 NCGC00094358-04 NCGC00094358-05 NCGC00094358-06 NCGC00094358-07 NCGC00094358-08 NCGC00094358-09 NCGC00094358-13 Neovitamin A acid Neovitamin a acid Prestwick2_000256 Prestwick3_000256 Prestwick_642 R 3255 R3255_SIGMA Retinoate Retinoic acid Ro 4 3780 Ro 4-3780 Ro 43780 Ro-4-3780 Ro-43780 Roaccutan Roaccutane Roacutan SAM002548955 SMR000471891 SPECTRUM1502013 Sotret Sotret (TN) Spectrum5_001795 Spectrum5_001937 Teriosal UNII-EH28UP18IF Zenatane cis-RA cis-Retinoate cis-Retinoic acid isotretinoino |
| | 9 | | Bevacizumab | approved, investigational | Phase 3, Phase 2, Phase 1 | 1875 | 216974-75-3 | | 216974-75-3 Avastin Avastin (TN) Bevacizumab Bevacizumab (genetical recombination) | Bevacizumab (genetical recombination) (JAN) D06409 R-435 anti-VEGF monoclonal antibody antiVEGF bevacizumab | |
| | 10 | | Dacarbazine | approved, investigational | Phase 2, Phase 3, Phase 1 | 411 | 4342-03-4 | 5351166 | (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide (Dimethyltriazeno)imidazolecarboxamide 37626-23-6 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide 4-(Dimethyltriazeno)imidazole-5-c arboxamide 4-(Dimethyltriazeno)imidazole-5-carboxamide 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide 4342-03-4 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide 5-(Dimethyltriazeno)-4-imidazolecarboxamide 5-(Dimethyltriazeno)imidazole-4-carboxamide 5-(Dimethyltriazeno)imidazole-4-carboximide 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide 94361-71-4 AC1NQXVV AC1NS01W AC1NS4BN AI3-52825 BPBio1_000428 BRD-K35520305-001-07-8 BSPBio_000388 BSPBio_002091 Biocarbazin Biocarbazine Biocarbazine R C6H10N6O CAS-891986 CCRIS 190 CHEBI:4305 CHEMBL476 CID5281007 CID5351166 CID5353562 Carboxamide, Dimethyl Imidazole D00288 D003606 D2390_SIGMA D3634 DB00851 DIC DTCI DTIC DTIC Dome DTIC, DTIC-Dome, Dacarbazine DTIC-Dome DTICDome DTIE Dacarbazin Dacarbazina Dacarbazine Dacarbazine (JAN/USP/INN) Dacarbazine [USAN:INN:BAN:JAN] Dacarbazino Dacarbazino [INN-Spanish] Dacarbazinum Dacarbazinum [INN-Latin] | Dacatic Decarbazine Deticene Di-me-triazenoimidazolecarboxamide Di-methyl-triazenoimidazolecarboxamide Dimethyl Imidazole Carboxamide Dimethyl Triazeno Imidazole Carboxamide Dimethyltriazenoimidazolecarboxamide DivK1c_000326 Dtic-Dome Dtic-Dome (TN) Dtic-dome (tn) EINECS 224-396-1 HE1150000 HMS1569D10 HMS2090A20 HMS2091I20 HMS501A08 HSDB 3219 I06-2280 I14-1659 ICDMT ICDT IDI1_000326 Imidazole Carboxamide Imidazole Carboxamide, Dimethyl Imidazole carboxamide KBio1_000326 KBio2_001364 KBio2_003932 KBio2_006500 KBio3_001311 KBioGR_000896 KBioSS_001364 LS-119 MLS001332543 MLS001332544 MolPort-003-666-153 MolPort-003-846-120 MolPort-006-709-420 NCGC00016986-01 NCGC00091861-01 NCGC00091861-02 NCGC00091861-03 NCGC00091861-04 NCI-C04717 NCI60_004053 NCIMech_000261 NINDS_000326 NIOSH/HE1150000 NPFAPI-05 NSC 45388 NSC-45388 NSC45388 Prestwick0_000574 Prestwick1_000574 Prestwick2_000574 Prestwick3_000574 Prestwick_904 S1221_Selleck SMP2_000251 SMR000857131 SPBio_001075 SPBio_002607 SPECTRUM1500218 ST51014976 Spectrum2_001148 Spectrum3_000366 Spectrum4_000308 Spectrum5_000823 Spectrum_000884 UNII-7GR28W0FJI WLN: T5M CNJ DVZ ENUNN1&1 dacarbazine | |
| | 11 | | Leflunomide | approved, investigational | Phase 3 | 62 | 75706-12-6 | 3899 | 210165-51-8 4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl 4-isoxazolecarboxamide,5-methyl-N-(4-(trifluoromethyl)phenyl) 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide 5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide 5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide) 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide 5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide 5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide 75706-12-6 A77 1486 AB00052389 AC-6796 AC1L1GYK AC1Q2EVA AKOS000265193 AP-501/42475599 Arava Arava (TN) Arava, Leflunomide Aventis Behring Brand of Leflunomide Aventis Brand of Leflunomide Aventis Pharma Brand of Leflunomide BIDD:PXR0189 BPBio1_000930 BRD-K78692225-001-03-9 BSPBio_000844 C045463 C07905 CAS-75706-12-6 CHEBI:6402 CHEMBL960 CID3899 D00749 DB01097 DivK1c_000916 EU-0100649 HMS1570K06 HMS1922M06 HMS2090O12 HMS502N18 HSDB 7289 HWA 486 HWA-486 Hoechst Brand of Leflunomide I06-2131 IDI1_000916 KBio1_000916 KBio2_000802 KBio2_003370 KBio2_005938 KBioSS_000802 L 5025 L5025_SIGMA | LS-86580 Leflunomid Leflunomida Leflunomida [INN-Spanish] Leflunomide Leflunomide (JAN/USAN/INN) Leflunomide [USAN:INN] Leflunomidum Leflunomidum [INN-Latin] Lefunomide Lefunomide [INN-Spanish] Lefunomide [Inn-Spanish] Lopac-L-5025 Lopac0_000649 MLS-0003109.0001 MLS000069648 MLS001076267 MolPort-002-345-613 N-(4'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide N-(4-trifluoromethyphenyl)-5-methylisoxazole-4-carboxamide NCGC00015610-01 NCGC00015610-02 NCGC00015610-03 NCGC00015610-07 NCGC00015610-12 NCGC00022625-03 NCGC00022625-04 NCGC00022625-05 NCGC00022625-06 NCGC00022625-07 NCGC00022625-08 NINDS_000916 NSC677411 Prestwick0_000772 Prestwick1_000772 Prestwick2_000772 Prestwick3_000772 Prestwick_87 RS-34821 S1247_Selleck SMR000058209 SPBio_002783 SPECTRUM1503927 SU 101 SU 101 (pharmaceutical) SU-101 SU101 Spectrum5_000850 Spectrum_000322 TL8005179 UNII-G162GK9U4W ZINC00004840 alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-P-toluidide alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide leflunomide lefunamide | |
| | 12 | | Fentanyl | approved, illicit, investigational | Phase 3 | 705 | 437-38-7 | 3345 | 1-Phenethyl-4-(N-phenylpropionamido)piperidine 1-Phenethyl-4-N-propionylanilinopiperidine 437-38-7 5-22-08-00049 (Beilstein Handbook Reference) 80832-90-2 990-73-8 (citrate) AC1L1FQ2 Abstral Actiq BIDD:GT0555 BRN 0494484 CHEBI:119915 CHEMBL596 CID3345 D00320 DB00813 Duragesic Duragesic (TN) Duragesic-100 Duragesic-12 Duragesic-25 Duragesic-50 Duragesic-75 Durogesic EINECS 207-113-6 Fentanest Fentanil Fentanil [DCIT] Fentanila Fentanila [INN-Spanish] Fentanilo Fentanyl Fentanyl (JAN/USAN/INN) Fentanyl - Novaplus Fentanyl Citrate Fentanyl [INN:BAN] Fentanyl citrate Fentanyl-100 | Fentanyl-12 Fentanyl-25 Fentanyl-50 Fentanyl-75 Fentanylum Fentanylum [INN-Latin] HSDB 3329 IONSYS JNS020QD L001275 LS-124439 Lazanda Matrifen MolPort-003-847-369 N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-Phenethyl-4-piperidyl)propionanilide N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide N-Phenethyl-4-(N-propionylanilino)piperidine N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide NCGC00168252-01 Nasalfent Oprea1_152073 Oprea1_207148 PDSP1_000860 PDSP2_000846 Pentanyl Phentanyl Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI) R 4263 Rapinyl Sentonil Sublimase Sublimaze Subsys UNII-UF599785JZ fentanyl | |
| | 13 | | Trioxsalen | approved | Phase 3, Phase 1 | 40 | 3902-71-4 | 5585 | 2',4,8-Trimethylpsoralen 4,5',8-Trimethylpsoralen 4,8,5'-Trimethylpsoralen 6-Hydroxy-beta,2,7-trimethyl-5-benzofuranacrylic acid, delta-lactone Trimethylpsoralen Trioxisaleno | Trioxsalen Trioxysalen Trioxysalene Trioxysalenum Trisoralen trimethylpsoralen trioxysalen trisoralen |
| | 14 | | Temozolomide | approved, investigational | Phase 3, Phase 2, Phase 1 | 662 | 85622-93-1 | 5394 | 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide 3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide 3,4-dihydro-3-Methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one 85622-93-1 AC-758 AC1L1K9B BIDD:GT0204 BRN 5547136 Bio-0147 C047246 C6H6N6O2 CCRG 81045 CCRG-81045 CCRIS 8996 CHEBI:153686 CHEMBL810 CID5394 CPD000466338 D06067 DB00853 Essex brand of temozolomide HMS2051O12 HMS2090B08 I06-0149 I14-1943 LS-80558 M B 39831 M & B 39831 M&B 39831 M&B-39831 | M-39831 MB 39831 MLS000759447 MLS001424028 MLS002701861 Methazolastone NCGC00167429-01 NCGC00167429-02 NCI60_003316 NSC 362856 NSC-362856 NSC362856 SAM001246636 SMR000466338 STK623541 Sch 52365 Sch-52365 Schering brand of temozolomide Schering-Plough brand of temozolomide TL8005593 TMZ TMZ-Bioshuttle Temodal Temodal (TN) Temodar Temozolamide Temozolodida Temozolodida [Spanish] Temozolomid Temozolomida Temozolomide Temozolomide (JAN/USAN/INN) Temozolomide [INN:BAN] Temozolomidum Temozolomidum [Latin] Témozolomide UNII-YF1K15M17Y ZINC01482184 m & b 39831 temozolomide |
| | 15 | | Carmustine | approved | Phase 3, Phase 2, Phase 1 | 207 | 154-93-8 | 2578 | 1,3-BIS(CHLOROETHYL)-1-NITROSOUREA 1,3-Bis(.beta.-chloroethyl)-1-nitrosourea 1,3-Bis(2-chloroethyl)-1-nitrosourea 1,3-Bis(2-chloroethyl)nitrosourea 1,3-Bis(beta-chloroethyl)-1-nitrosourea 154-93-8 AC-10563 AC1L1DZQ AI3-52216 BCNU BCNU [Chloroethyl nitrosoureas] BRN 2049744 Becenum Becenun Bi CNU BiCNU BiCNU (TN) Bicnu Bicnu (tn) Bio-0118 Bis(2-chloroethyl)1-nitrosourea Bis(2-chloroethyl)nitrosourea Bis(chloroethyl)nitrosourea Bis-N,N'-(chloroethyl)nitrosourea Bischlorethylnitrosourea Bischlorethylnitrosurea Bischloroethyl nitrosourea Bischloroethyl nitrosourea [Chloroethyl nitrosoureas] Bischloroethylnitrosourea C 0400 C0400_SIGMA C5H11Cl2N3O2 CCRIS 810 CHEBI:3423 CHEMBL513 CID2578 Carmubris Carmustin Carmustina Carmustina [INN-Spanish] Carmustine Carmustine (USAN/INN) Carmustine [USAN:INN:BAN] Carmustinum Carmustinum [INN-Latin] D002330 D00254 DB00262 DTI 015 DivK1c_000835 EINECS 205-838-2 | EU-0100188 FDA 0345 FIVB FT-0083563 Gliadel Gliadel Wafer Gliadel, BCNU, NSC-409962, Becenun, Carmustine HMS2092J22 HMS502J17 I14-11976 IDI1_000835 KBio1_000835 KBio2_000745 KBio2_003313 KBio2_005881 KBioGR_001296 KBioSS_000745 LS-890 Lopac-C-0400 Lopac0_000188 MLS001333962 MolPort-003-665-505 N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA N,N'-Bis(2-chloroethyl)-N-nitrosourea NCGC00015204-01 NCGC00015204-02 NCGC00015204-06 NCGC00093665-01 NCGC00093665-02 NCGC00093665-03 NCGC00093665-04 NCI-C04773 NCI60_003931 NINDS_000835 NSC 409962 NSC-409962 NSC409962 Nitrumon Prestwick_997 S1521_Selleck SK 27702 SMR000058426 SRI 1720 STK624770 Spectrum4_000888 Spectrum5_000920 Spectrum_000265 UNII-U68WG3173Y WLN: ONN2GVM2G ZINC03830387 bis-chloroethylnitrosourea carmustine carmustine in ethanol |
| | 16 | | Dopamine | approved | Phase 3, Phase 1 | 3084 | 62-31-7, 51-61-6 | 681 | (3H)-Dopamine .Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride .alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane 1,2-Benzenediol, 4-(2-aminoethyl)- (9CI) 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium 153C5321-5FEE-4B0B-8925-F388F0EEEBD1 2-(3,4-Dihydroxyphenyl)ethylamine 2-(3,4-dihydroxyphenyl)ethylamine 2-benzenediol 3,4-Dihydroxyphenethylamine 3,4-Dihydroxyphenethylamine hydrochloride 3,4-Dihydroxyphenylethylamine 3,4-dihydroxyphenethylamine 3-Hydroxtyramine 3-Hydroxytyramine 3-Hydroxytyramine Hydrobromide 3-Hydroxytyramine hydrochloride 4-(2-Aminoethyl)-1, 4-(2-Aminoethyl)-1,2-benzenediol 4-(2-Aminoethyl)-1,2-bezenediol 4-(2-Aminoethyl)-Pyrocatechol 4-(2-Aminoethyl)benzene-1,2-diol 4-(2-Aminoethyl)catechol 4-(2-Aminoethyl)pyrocatechol 4-(2-Aminoethyl)pyrocatechol hydrochloride 4-(2-aminoethyl)-pyrocatechol 50444-17-2 51-61-6 62-31-7 (HYDROCHLORIDE) AC1L19S5 AC1Q54AX AC1Q54AY AKOS003790978 ASL 279 BIDD:ER0506 BPBio1_001123 BSPBio_001932 Biomol-NT_000001 C03758 CHEBI:18243 CHEMBL59 CID681 D07870 DB00988 Deoxyepinephrine DivK1c_000780 Dopamin Dopamina Dopamina [INN-Spanish] Dopamine Dopamine (INN) Dopamine (USAN)(*hydrochloride*) Dopamine Hcl Dopamine Hydrochloride Dopamine [INN:BAN] Dopaminum Dopaminum [INN-Latin] Dopastat Dophamine Dynatra EINECS 200-110-0 HSDB 3068 Hydroxytyramin Hydroxytyramine IDI1_000780 IP 498 Intropin Intropin [*hydrochloride*] | KBio1_000780 KBio2_001492 KBio2_002388 KBio2_002484 KBio2_004060 KBio2_004956 KBio2_005052 KBio2_006628 KBio2_007524 KBio2_007620 KBio3_001152 KBio3_002867 KBio3_002962 KBioGR_001129 KBioGR_002388 KBioGR_002484 KBioSS_001492 KBioSS_002393 KBioSS_002491 KW-3-060 L-DOPAMINE L000232 LDP LS-159 Lopac-H-8502 Lopac0_000586 Medopa (TN) MolPort-001-641-000 NCGC00015519-01 NCGC00015519-08 NCGC00096050-01 NCGC00096050-02 NCGC00096050-03 NCGC00096050-04 NCGC00096050-05 NINDS_000780 NSC 173182 NSC169105 NSC173182 Oprea1_088821 Oxytyramine Pyrocatechol, 4-(2-aminoethyl)- (8CI) Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride Revimine Revivan SPBio_001205 SPECTRUM1505155 ST048774 STK301601 Spectrum2_001023 Spectrum3_000406 Spectrum4_000525 Spectrum5_000945 Spectrum_001012 UNII-VTD58H1Z2X UPCMLD0ENAT5885989:001 a-(3,4-Dihydroxyphenyl)-b-aminoethane alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane cMAP_000036 cMAP_000065 dopamine hydroxytyramine intropin m-Hydroxytyramine hydrochloride nchembio.105-comp9 nchembio.107-comp4 nchembio.284-comp1 nchembio.78-comp16 nchembio.89-comp3 nchembio705-8 nchembio801-comp8 |
| | 17 | | Cyproheptadine | approved | Phase 3 | 15 | 129-03-3 | 2913 | 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine 129-03-3 4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine 4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine 4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine 41354-29-4 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene 5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene 5-20-08-00500 (Beilstein Handbook Reference) AC1L1ER8 AKOS004119847 Axoprol BIDD:GT0324 BPBio1_000096 BPBio1_000155 BRD-K28143534-001-01-4 BRD-K28143534-003-03-6 BRN 1685976 BSPBio_000086 Biomol-NT_000131 C06935 CAS-969-33-5 CCRIS 5232 CHEBI:4046 CHEMBL516 CID2913 CYPROHEPTADINE Ciproheptadina Ciproheptadina [INN-Spanish] Ciprovit Ciprovit (TN) Cypoheptadine Cyproheptadiene Cyproheptadin Cyproheptadine Cyproheptadine (INN) | Cyproheptadine Hcl Cyproheptadine Hydrochloride Cyproheptadine [INN:BAN] Cyproheptadinum Cyproheptadinum [INN-Latin] D07765 DB00434 Dibenzosuberonone/Cyproheptadine Dihexazin Dronactin EINECS 204-928-9 Eiproheptadine Glutodina HMS2090P20 HSDB 3048 L001016 LS-114933 Lopac-C-6022 Lopac0_000246 MK 141 MolPort-002-507-777 NCGC00015252-01 NCGC00015252-02 NCGC00015252-03 NCGC00015252-09 NCGC00024293-02 NCGC00024293-04 NCGC00024293-05 Oprea1_498140 PDSP1_001229 PDSP2_001213 Periactin Periactine Periactinol Prestwick0_000103 Prestwick1_000103 Prestwick2_000103 Prestwick3_000103 SPBio_002025 STK802098 Tocris-0996 UNII-2YHB6175DO Viternum nchembio.559-comp10 | |
| | 18 | | Histamine Phosphate | approved | Phase 3 | 906 | 51-74-1 | 65513 | 1H-Imidazole-4-ethanamine, phosphate (1:2) 2-Imidazol-4-ylethylamine orthophosphoric acid (1:2) 4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate) 4-(2-Aminoethyl)imidazole di-acid phosphate 4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate 51-74-1 53623-99-7 74-56-6 AC1L23E4 CID65513 D04445 DB00667 EINECS 200-118-4 | H0147 Histamine Positive Skin Test Control Histamine Positive skin test control Histamine acid phosphate Histamine biphosphate Histamine dihydrogen phosphate Histamine diphosphate Histamine phosphate (1:2) Histamine phosphate (TN) Histamine phosphate (USP) Histamine phosphate [USP] Histamine positive Histaminum LS-78569 UNII-QWB37T4WZZ |
| | 19 | | Tretinoin | approved, investigational, nutraceutical | Phase 3, Phase 2, Phase 1 | 210 | 302-79-4 | 5538, 444795 | (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid (all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid .beta.-Retinoic acid 13497-05-7 (hydrochloride salt) 15-Apo-beta-caroten-15-oic acid 187175-63-9 1n4h 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl) 302-79-4 5300-03-8 56573-65-0 7005-78-9 9(Z)-Retinoic acid 9-cis-RA A-Acido (Argentina) A-Vitaminsyre A-Vitaminsyre [Denmark] AC-6824 AC1L9GWO AC1Q1J2J AGN 100335 AGN 192013 AKOS000280845 ALRT 1057 AT-RA ATRA Aberel Aberela Aberela [Norway] Accutane Roche Acid A Vit (Belgium, Netherlands) Acid, Retinoic Acid, Vitamin A Acid, all-trans-Retinoic Acid, beta-all-trans-Retinoic Acid, trans-Retinoic Acide retinoique (French) Acide retinoique (French) (DSL) Acide retinoique (french) (dsl) Acnavit Acnavit [Denmark] Airol Aknefug Aknoten Alitretinoin All Trans Retinoic Acid All Trans-Retinoic Acid All-(E)-Retinoate All-(E)-Retinoic acid All-trans Retinoic Acid All-trans-Retinoate All-trans-Retinoic acid All-trans-Tretinoin All-trans-Vitamin A acid All-trans-Vitamin A1 acid Alltrans-retinoic acid Amnesteem Atra-IV Atragen Atralin Avita Avita (TN) Avita Gel Avitoin Avitoin [Norway] BAL4079 BIDD:GT0483 BIDD:PXR0081 BML2-E05 BPBio1_000082 BRN 2057223 BSPBio_000074 BSPBio_001500 Betarretin C00777 CCRIS 3294 CCRIS 7098 CHEBI:15367 CHEMBL38 CID444795 CPD000058245 Claravis Cordes VAS [Germany] Cordes vas D00094 D014212 DB00523 DB00755 DB00982 Dermairol EINECS 206-129-0 EU-0101061 Effederm Effederm [France] Epi-aberel Eudyna HMS1361K22 HMS1568D16 HMS1791K22 HMS1921D14 HMS1989K22 HMS2089D20 HMS2092N11 HMS502N05 HSDB 2169 HSDB 7186 I04-0008 I14-2351 IDI1_000903 IDI1_033970 Isotretinoin Retinoic acid L000833 LGD 100057 LMPR01090019 LS-1154 Lopac0_001061 Lsotretinoin MLS000028588 MLS001076515 MLS002207234 MLS002222211 MolPort-000-883-857 NCGC00017280-06 NCGC00017280-17 NCGC00021808-04 | NCGC00021808-05 NCGC00021808-06 NCGC00021808-07 NCGC00021808-09 NCGC00021808-14 NCGC00021808-15 NSC 122758 NSC-122758 NSC122758 Nexret Obagi PDT-002-002 Panretin Gel Panretyn Potassium Salt, Tretinoin Prestwick2_000257 Prestwick3_000257 Prestwick_424 R 2625 R0064 R2625_SIGMA REA RETINOIC ACID, ALL TRANS RETINOIC acid Refissa Renova Renova (TN) Retacnyl Retin A Retin A (TN) Retin-A Retin-A Micro Retin-a Retin-a Micro Retinoate Retinoic acid Retinoic acid, all-trans- (8CI) Retinova Retionic Acid Retionic acid Retisol-A Retisol-a Ro 1-5488 S1653_Selleck SAM002264647 SMR000058245 SPECTRUM1502016 SR-01000000239 SR-01000000239-14 ST057075 Salt, Tretinoin Potassium Salt, Tretinoin Sodium Salt, Tretinoin Zinc Sodium Salt, Tretinoin Solage Sotret Spectrum5_001746 Spectrum5_001933 Stieva-A Stieva-a Stieva-a Forte TRETINON Tretin M Tretin m Tretin-x Tretin.x Tretinoin Tretinoin (JAN/USP/INN) Tretinoin (TN) Tretinoin 0.1% cream or placebo Tretinoin Cream Tretinoin Gel Microsphere Tretinoin Potassium Salt Tretinoin Sodium Salt Tretinoin Zinc Salt Tretinoin [USAN:INN:BAN] Tretinoin/All-Trans Retinoic Acid Tretinoina Tretinoina [INN-Spanish] Tretinoine Tretinoine (French) Tretinoine (french) (einecs) Tretinoine [INN-French] Tretinoino Tretinoino [INN-Spanish] Tretinoinum Tretinoinum [INN-Latin] Tretinx Tri-Luma Trétinoïne UNII-1UA8E65KDZ UNII-5688UTC01R UPCMLD-DP097 Vesanoid Vesanoid (TN) Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin Vesnaroid Vitamin A acid Vitinoin WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1 WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1 Zinc Salt, Tretinoin [3H]Retinoic acid all trans-Retinoic acid all-(E)-Retinoic acid all-(e)-Retinoic acid all-trans-Retinoic acid all-trans-Tretinoin all-trans-Vitamin A acid all-trans-Vitamin A1 acid all-trans-Vitamin a acid all-trans-Vitamin a1 acid all-trans-b-Retinoic acid all-trans-beta-Retinoic acid b-Retinoic acid beta all trans Retinoic Acid beta-Ra beta-Retinoate beta-Retinoic Acid beta-Retinoic acid beta-all-trans-Retinoic acid bmse000562 nchembio.154-comp2 trans Retinoic Acid trans-Retinoate trans-Retinoic acid tretinoin tretinoin liposome tretinoine (French) (EINECS) | |
| | 20 | | Angiogenesis Inhibitors | | Phase 3, Phase 2, Phase 1 | 3688 | | | | 21 | | Veliparib | | Phase 2, Phase 3, Phase 1 | 88 | | 11960529 | | ABT-888 Veliparib veliparib |
| | 22 | | O(6)-benzylguanine | | Phase 3, Phase 2, Phase 1 | 34 | | | | 23 | | Liver Extracts | | Phase 3, Phase 2, Phase 1 | 3572 | | | | 24 | | Analgesics, Opioid | | Phase 3 | 2304 | | | | 25 | | Tubulin Modulators | | Phase 3, Phase 1, Phase 2 | 4279 | | | | 26 | | Angiogenesis Modulating Agents | | Phase 3, Phase 2, Phase 1 | 3611 | | | | 27 | | Antibodies, Monoclonal | | Phase 3, Phase 2, Phase 1 | 2413 | | | | 28 | | Mitogens | | Phase 3, Phase 2, Phase 1 | 1386 | | | | 29 | | Antineoplastic Agents, Alkylating | | Phase 3, Phase 2, Phase 1 | 3406 | | | | 30 | | Immunologic Factors | | Phase 3, Phase 1, Phase 2 | 18483 | | | | 31 | | Immunoglobulins | | Phase 3, Phase 2, Phase 1 | 4477 | | | | 32 | | Anesthetics | | Phase 3 | 7385 | | | | 33 | | Endothelial Growth Factors | | Phase 3, Phase 2, Phase 1 | 328 | | | | 34 | | Antibodies | | Phase 3, Phase 2, Phase 1 | 4477 | | | | 35 | | Analgesics | | Phase 3, Phase 2, Phase 1 | 9358 | | | | 36 | | Cholinergic Agents | | Phase 3, Phase 2 | 3243 | | | | 37 | | Cholinesterase Inhibitors | | Phase 3, Phase 2 | 498 | | | | 38 | | Antineoplastic Agents, Phytogenic | | Phase 3, Phase 2, Phase 1 | 4294 | | | | 39 | | Anesthetics, General | | Phase 3 | 2274 | | | | 40 | | Anesthetics, Intravenous | | Phase 3 | 1943 | | | | 41 | | Central Nervous System Depressants | | Phase 3, Phase 2, Phase 1 | 10016 | | | | 42 | | Peripheral Nervous System Agents | | Phase 3, Phase 2, Phase 1 | 18510 | | | | 43 | | Alkylating Agents | | Phase 3, Phase 2, Phase 1 | 3582 | | | | 44 | | Narcotics | | Phase 3 | 2709 | | | | 45 | | pancreatic polypeptide | | Phase 3, Phase 1 | 20 | | | | 46 | | Neurotransmitter Agents | | Phase 3, Phase 2, Phase 1 | 14795 | | | | 47 | | Hematoporphyrins | | Phase 3 | 10 | | | | 48 | | Photosensitizing Agents | | Phase 3, Phase 1, Phase 2 | 374 | | | | 49 | | Central Nervous System Stimulants | | Phase 3, Phase 2 | 1721 | | | | 50 | | Nootropic Agents | | Phase 3, Phase 2 | 604 | | |
Interventional clinical trials: (show top 50)
(show all 453)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma | Completed | NCT00017147 | Phase 3 | | 2 | Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme | Completed | NCT00820963 | Phase 3 | | 3 | Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain | Completed | NCT00538850 | Phase 3 | | 4 | E-MOSAIC Electronic Tool to Monitor Symptoms | Completed | NCT00477919 | Phase 3 | | 5 | Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors | Completed | NCT00369785 | Phase 3 | | 6 | High Light and Low Light Dose PDT in Glioma | Completed | NCT00118222 | Phase 3 | | 7 | Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma | Completed | NCT00052455 | Phase 3 | | 8 | Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Completed | NCT00006353 | Phase 3 | | 9 | Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma | Completed | NCT00003916 | Phase 3 | | 10 | SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme | Completed | NCT00003293 | Phase 3 | | 11 | Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme | Completed | NCT00002545 | Phase 3 | | 12 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | Recruiting | NCT02152982 | Phase 2, Phase 3 | | 13 | Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Active, not recruiting | NCT00304031 | Phase 3 | | 14 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | Active, not recruiting | NCT01480479 | Phase 3 | | 15 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | Active, not recruiting | NCT00884741 | Phase 3 | | 16 | Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme | Active, not recruiting | NCT00482677 | Phase 3 | | 17 | Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas | Active, not recruiting | NCT00003788 | Phase 3 | | 18 | Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer | Terminated | NCT01132547 | Phase 3 | | 19 | Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors | Terminated | NCT00031798 | Phase 3 | | 20 | Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas | Withdrawn | NCT00003564 | Phase 3 | | 21 | Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | Completed | NCT00525525 | Phase 2 | | 22 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | Completed | NCT00597402 | Phase 2 | | 23 | Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas | Completed | NCT00612339 | Phase 2 | | 24 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | Completed | NCT00335764 | Phase 1, Phase 2 | | 25 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | Completed | NCT00187486 | Phase 2 | | 26 | Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | Completed | NCT00402116 | Phase 1, Phase 2 | | 27 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | Completed | NCT00165477 | Phase 2 | | 28 | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | Completed | NCT00979017 | Phase 2 | | 29 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | Completed | NCT00433381 | Phase 2 | | 30 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | Completed | NCT00305864 | Phase 1, Phase 2 | | 31 | GW572016 to Treat Recurrent Malignant Brain Tumors | Completed | NCT00107003 | Phase 2 | | 32 | AMG 102 and Avastin for Recurrent Malignant Glioma | Completed | NCT01113398 | Phase 2 | | 33 | BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) | Completed | NCT01856933 | Phase 2 | | 34 | Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | Completed | NCT00671970 | Phase 2 | | 35 | Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | Completed | NCT00615927 | Phase 2 | | 36 | Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan | Completed | NCT00613028 | Phase 2 | | 37 | Ph II Bevacizumab + Etoposide for Pts w Recurrent MG | Completed | NCT00612430 | Phase 2 | | 38 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | Completed | NCT00611325 | Phase 2 | | 39 | Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme | Completed | NCT00672243 | Phase 2 | | 40 | Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma | Completed | NCT00028795 | Phase 2 | | 41 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | Completed | NCT01836549 | Phase 2 | | 42 | BIBF 1120 for Recurrent High-Grade Gliomas | Completed | NCT01380782 | Phase 2 | | 43 | A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | Completed | NCT00995007 | Phase 2 | | 44 | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | Completed | NCT00667394 | Phase 2 | | 45 | Dose-Intense Temozolomide in Recurrent Glioblastoma | Completed | NCT00657267 | Phase 2 | | 46 | Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma | Completed | NCT00354913 | Phase 2 | | 47 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | Completed | NCT00980343 | Phase 2 | | 48 | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | Completed | NCT00641706 | Phase 2 | | 49 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | Completed | NCT00540722 | Phase 2 | | 50 | Sunitinib in Treating Patients With Recurrent Malignant Gliomas | Completed | NCT00499473 | Phase 2 |
Cochrane evidence based reviews: gliosarcoma
|
